J Biol Chem, Vol. 274, Issue 42, 29937-29943, October 15, 1999
Interaction of Macrophage-stimulating Protein with Its
Receptor
RESIDUES CRITICAL FOR
CHAIN BINDING AND EVIDENCE FOR
INDEPENDENT
CHAIN BINDING*
Alla
Danilkovitch
§,
Maria
Miller¶, and
Edward J.
Leonard
From the
Laboratory of Immunobiology, NCI-Frederick
Cancer Research and Development Center and ¶ Macromolecular
Structure Laboratory, NCI-Frederick Cancer Research and Development
Center, ABL-Basic Research Program, Frederick, Maryland 21702
 |
ABSTRACT |
Macrophage-stimulating protein (MSP) and
hepatocyte growth factor/scatter factor (HGF/SF) are
plasminogen-related growth and motility factors that interact with
cell-surface protein tyrosine kinase receptors. Each one is a
heterodimeric protein comprising a disulfide-linked
chain and a
serine protease-like
chain. Despite structural similarities between
MSP and HGF, the primary receptor binding site is located on the
chain of HGF/SF but on the
chain of MSP. To obtain insight into the
structural basis for MSP
chain binding,
chain structure was
modeled from coordinates of an existing model of the HGF
chain. The
model revealed that the region corresponding to the S1 specificity
pocket in trypsin is filled by the
Asn682/Glu648 interacting pair, leaving a
shallow cavity for possible
chain interaction with the receptor.
Mutants in this region were created, and their binding characteristics
were determined. A double mutation of
Asn682/Glu648 caused diminished binding of the
chain to the MSP receptor, and a single mutation of neighboring
Arg683 completely abolished binding. Thus, this region of
the molecule is critical for binding. We also found that at equimolar
concentrations of free
and
chains,
chain binding to
receptor was detectable, at levels considerably lower than
chain
binding. The EC50 values determined by quantitative
enzyme-linked immunosorbent assay are 0.25 and 16.9 nM for
and
chain, respectively. The data suggest that MSP has two
independent binding sites with high and low affinities located in
and
chain, respectively, and that the two sites together mediate
receptor dimerization and subsequent activation.
 |
INTRODUCTION |
Macrophage-stimulating protein
(MSP)1 is a 78-kDa growth and
motility factor that belongs to a plasminogen-related kringle protein
family (1, 2). It is most closely related to hepatocyte growth
factor/scatter factor (HGF/SF), to which it has 45% sequence similarity (3). Mature MSP acts on a number of cell types including tissue macrophages, epithelia, and hematopoietic cells (4). Actions on
macrophages include stimulation of motility (5), induction of
phagocytosis of serum complement-coated erythrocytes (1), inhibition of
inducible NO synthase up-regulation by inflammatory stimuli (6), and
induction of interleukin 6 secretion.2 MSP induces
adhesion, motility, and replication of epithelial cells, and it can
prevent the apoptosis that occurs when epithelial cells are prevented
from attachment to a substrate (7). MSP mediates its effects by binding
to and activating a cell receptor tyrosine kinase known as RON in
humans (8, 9) and STK in mice (10, 11). Closely related HGF/SF also has
mitogenic and motogenic actions on epithelial cell types (12) that
express Met, the specific receptor for this ligand (13). HGF has a
morphogenetic role in development and tissue repair (14). Specific
mutations in Met are oncogenic in both experimental models (for a
review see Ref. 15) and in sporadic human cancers (16).
In contrast to other members of this plasminogen-related family, which
are serine proteases, MSP and HGF are devoid of enzymatic activity
because of catalytic triad mutations. However, they have retained the
proteolytic mechanism of activation of the zymogens of the family (17).
Thus, MSP is synthesized by hepatocytes (18) as biologically inactive
single chain pro-MSP and is converted at extravascular sites to active
MSP by trypsin-like proteases, which cleave at
Arg483/Val484 (19) to make a disulfide-linked

chain heterodimer (20). MSP and HGF have 40% sequence
similarity to plasminogen and the same domain organization. The three
proteins evolved from a common ancestor (21). Features of the
chain
of MSP and HGF include an N-terminal domain (N domain) corresponding to
the plasminogen preactivation peptide, four kringles, and a segment
that terminates in the cleavage site for activation; the
chain is
the serine protease-like domain. HGF binds with high affinity to its
receptor via the
chain. The N domain makes a critical contribution
to HGF binding, since N domain deletion mutants have reduced or absent biological activity (22, 23) and fail to inhibit binding of HGF to
Met-expressing target cells (23). In contrast to HGF, studies with
125I-labeled subunits of MSP showed that the
chain
bound with high affinity to RON, whereas
chain binding was
undetectable (24). Mutant MSP lacking the
chain is biologically
inactive (25). Therefore, despite the similarity in domains of HGF and
MSP, the loci for high affinity binding to their receptors are
completely different.
To explore the basis of MSP
chain binding to RON, we took advantage
of a recently published energy-minimized three-dimensional model of the
chain of HGF (21). We used the HGF model coordinates to make a
comparable model of the MSP
chain to look for features that might
account for its binding properties. By analogy to proteases, MSP and
HGF correspond to enzymes, and their receptors correspond to enzyme
substrates. From this viewpoint, regions of the MSP serine
protease-like domain of particular interest for binding to receptor
would include the catalytic site and several surface loops that define
the substrate binding cleft for chymotrypsin-like proteases (26). Our
model of the MSP
chain revealed features that were postulated to
account for its binding to RON. Mutagenesis studies reported herein
established that the region corresponding to an enzyme S1 site is
essential for
chain binding to RON.
Our experiments also revealed binding to RON-expressing cells of
MSP-free
chain, which was a small fraction of the amount of
chain binding. This suggests that MSP has two receptor binding sites, a
high affinity site in the
chain and a low affinity site in the
chain. The result supports a recent hypothesis that ligand-induced RON
dimerization by MSP is mediated by a single ligand molecule, which
binds to a receptor via the
chain, after which a second receptor is
engaged by the
chain (27).
 |
EXPERIMENTAL PROCEDURES |
Materials--
Human recombinant MSP and free
and
chains
were from Toyobo (Osaka, Japan) and R & D Systems (Minneapolis, MN).
Rabbit and mouse anti-MSP antibodies were described (28). Madin-Darby canine kidney (MDCK) and CHO-K1 cells were from ATCC (Manassas, VA).
MDCK cells stably transfected with a human RON cDNA (clone RE7)
were described (9).
Modeling of the MSP
Chain--
Inasmuch as the MSP
chain
has 48% amino acid identity to the HGF
chain, we used the
coordinates of the three-dimensional model of the HGF
chain (21) to
model the MSP
chain structure. Side chains of HGF were replaced
with MSP side chains according to the alignment shown in Fig. 1.
Positions of the conserved backbone atoms were not altered. The loop
comprising residues 525-533 was modeled to reflect the experimentally
demonstrated disulfide bridge between Cys527 and
Cys562 (19). Subsequently the positions of several side
chains were adjusted manually (program FRODO and its silicon graphics
version TOM (29)) to remove bad contacts and to optimize electrostatic and hydrophobic interactions. The model was then energy-minimized using
program XPLOR (30) employing 250 cycles of the Powell conjugate
gradient algorithm.
Generation of Mutants of Wild Type Human MSP cDNA--
All
mutants were generated using the pAlterII (Promega, Madison, WI)
mutagenesis kit with mutagenic oligonucleotides as follows: for
R683Q, GGAATTATAATCCCCAACCAAGTATGCGCAAGGTCCCGC; for E648G/D682G, ATGTGCACTGGGGGACTGTTG/ATAATCCCCGGCCGAGTATGC. For stable
transfection of eukaryotic cells wild type and mutant MSP were
re-cloned into pCL-neo (Promega, Madison, WI).
Cell Culture and Transfection of Recombinant MSP--
CHO-K1
cells (ATCC) were grown in Dulbecco's modified Eagle's medium
supplemented with 8% fetal calf serum. For stable expression of MSP,
cells in 10-cm dishes were transfected with 10 µg of MSP cDNA by
Superfect reagent (Qiagen, Santa Clarita, CA) and placed in medium with
500 µg/ml geneticin (Life Technologies, Inc.). After selection,
single colonies were cloned, and clones with highest equal expression
of wild type and mutant MSP were selected. The concentration of
recombinant MSP in culture supernatants was measured by sandwich
ELISA.
Sandwich ELISA for MSP--
The concentration of secreted
recombinant MSP in cell culture supernatants was determined by sandwich
ELISA (28). Concentrations were calculated by reference to a standard
curve generated with wild type recombinant human MSP.
Immunoprecipitation and Western Blotting--
MSP from culture
supernatants was immunoprecipitated by rabbit polyclonal anti-MSP
antibodies conjugated to Sepharose beads. Immunoprecipitates were
washed and boiled after addition of 2× sample buffer. After PAGE,
proteins were transferred to a nitrocellulose membrane (Amersham
Pharmacia Biotech). MSP was detected with rabbit anti-MSP antibodies.
ECL (Amersham Pharmacia Biotech) was used for visualization of the
peroxidase complex.
Metabolic Labeling of MSP--
CHO-K1 cells stably expressing
wild type or mutant MSP were incubated for 48 h with
35S-easy labeling mix ([35S]cysteine and
[35S]methionine) (NEN Life Science Products) in
methionine- and cysteine-free Dulbecco's modified Eagle's medium
(Life Technologies, Inc.) supplemented with 8% dialyzed fetal calf
serum. The quality and quantity of 35S-labeled MSP were
analyzed by immunoprecipitation and SDS-PAGE under reducing and
non-reducing conditions.
Binding and Competition Assays with 35S-Labeled
MSP--
MDCK-RE7 cells with stably expressed RON receptor were used.
The parental MDCK cell line without detectable expression of RON was
used as a negative control. Five ml of supernatant containing equal
concentrations of 35S-labeled wild type or mutant MSP were
added to 5 × 106 RE7 or MDCK cells. Cells were
equilibrated for 4 h at 4 °C. After equilibration, cells were
washed 3 times with phosphate-buffered saline and lysed in lysis buffer
(50 mM HEPES, pH 7.4, 150 mM NaCl, 10%
glycerol, 1 mM EDTA, 1 mM sodium orthovanadate,
10 mM sodium pyrophosphate, 100 mM NaF, 1%
Triton X-100, 10 µg/ml leupeptin, 10 units/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride). After clarification,
lysates were immunoprecipitated by equilibration overnight at 4 °C
with rabbit anti-MSP antibodies coupled to Sepharose. Then
immunoprecipitates were washed 3 times with HNTG buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol,
0.1% Triton X-100) and analyzed by SDS-PAGE. Protein bands were
detected by radioautography. For competition assays, 50 nM
unlabeled recombinant human MSP or free
or
chains were
equilibrated with cells together with 35S-labeled MSP
culture supernatants.
Binding of Free
Chain to RON Receptor--
RE7 cells (5 × 106/well) with stably expressed RON receptor and
parental MDCK cells as a negative control were equilibrated for 4 h at 4 °C in 5 nM free recombinant
chain or MSP.
Cells were then washed, and cell lysates were processed as described above, except that detection of protein bands was by immunoblotting with polyclonal rabbit anti-MSP antibodies.
RON-ELISA--
ELISA microtiter plates were coated overnight at
4 °C with the recombinant mouse MSP receptor RON/Fc (rmRON/Fc)
chimera (R & D Systems, Inc.) (100 µl/well at 0.5 µg/ml in
carbonate-bicarbonate buffer, pH 9.6). Nonspecific binding sites were
blocked with 1% bovine serum albumin for 1 h at 37 °C.
RON-coated ELISA plates were then incubated for 2 h with a series
of 2-fold dilutions of human recombinant MSP (highest concentration 6.4 nM), free
chain (highest concentration 8 nM) or free
chain (highest concentration 320 nM). ELISA plates were washed 3 times with TBS/Tween 20 after this and subsequent steps. Plates were then incubated with rabbit
polyclonal anti-MSP for an additional 2 h. The rabbit anti-MSP
antibodies recognize MSP and separate free chains with comparable
sensitivity, as determined by direct ELISA in which microtiter wells
were coated with MSP or free
or
chain standards (data not
shown). Bound rabbit anti-MSP was detected by equilibration with
alkaline phosphatase-conjugated anti-rabbit IgG. Substrate 104 (Sigma)
was used for quantifying alkaline phosphatase activity. Absorbance at
405 nM was measured with an ELISA reader. At least three
independent experiments were performed. To quantify ligand binding
affinity, EC50 values were calculated by using a
four-parameter nonlinear fitting algorithm (31).
 |
RESULTS |
Model of the Serine Protease Domain of MSP--
The structural
core of all chymotrypsin-like serine proteases is composed of two
six-stranded
barrels, with the active site in a crevice between
these two domains. MSP and HGF
chains have 48% sequence identity
(Fig. 1) and higher than 30% sequence
similarity to several mammalian serine proteases. Features in common
include the same bilobed core, several surface loops, and a C-terminal helix (Fig. 2A). Furthermore,
despite loss of enzymatic activity because of catalytic triad
mutations, the geometry of the regions of MSP that correspond to the
active site of serine proteases has been conserved. This includes
mutated catalytic triad residues Gln522(57),3
Gln568(102), and Tyr661(195) (colored
magenta in Figs. 1 and 2) at the junction of the
barrels, the same conformation of the
Gly655(189)-Asp660(194) segment (colored
violet) necessary for the formation of an oxyanion hole and
a mature substrate specificity pocket. The critical interaction
maintaining active site architecture, a salt bridge between
Asp660(194) and the NH3+
group from the N-terminal Val of the
chain, is conserved.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 1.
Sequence alignment of bovine trypsin and
serine protease domains of HGF and MSP. Conserved cysteines are
marked in yellow; sequence homology between HGF and MSP is
shown in green. Residues corresponding to the catalytic
triad are shown in magenta. Numbering at the
top corresponds to that of 2PTN entry in the Protein Data
Bank. The open and filled bars under the sequence
show the locations of strands and helices, respectively.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 2.
A ribbon representation of the
three-dimensional model of MSP serine protease domain. -Strands
and C-terminal helix are shown in orange. Surface loop 1 (colored green) contains exclusively hydrophobic amino acids
Leu, Leu, Ala, Pro, and Val. Three Arg residues from loop 2 (red) and three from loop 3 (red) form a
prominent cluster of positive charge on the MSP surface. Segments with
conformation significantly different from that of chymotrypsinogen,
484(16)-489(21) and 645(189)-660(194) are colored violet.
Side chains of several key amino acids are also shown: mutated
catalytic triad, Gln522(57), Gln568(102),
Tyr661(195) in magenta; Glu648(184)
and Asn682(216) buried in the S1 substrate binding pocket
in azure; cluster of Arg residues in dark blue;
carbon atoms of residues critical for zymogen activation,
Val484(16), Asp660(194), and
His505(40) in green. B, close-up of
the region corresponding to the S1 specificity pocket of trypsin with
the side chains of critical residues. Coloring as in
A.
|
|
The residues critical for zymogen activation (for a review see Ref. 32)
are also conserved in MSP, suggesting that conversion to the
biologically active growth factor conformation mirrors the mechanism of
zymogen activation. In the zymogen form of the chymotrypsin-like
enzymes, the active site cleft is not completely formed.
His505(40) interacts with Asp660(194), and the
adjacent segment Gly655(189)-Asp660(194) is
oriented to the interior of the zymogen. Upon activation, Asp660(194) forms the salt bridge noted above with the
newly liberated N terminus, and segment
Gly655(189)-Asp660(194) (colored
violet in Fig. 2A) moves outward toward solvent to complete the active site cleft.
Surface loop features specific for MSP are noted in the legend of Fig.
2A. A detailed view of the region of MSP corresponding to
the substrate binding pocket and catalytic triad is shown in Fig.
2B. Several features distinguish MSP from trypsin in this region as follows: 1) The entrance to the large cylindrical S1 pocket
is blocked in MSP by Asn682(216) and
Ala692(226), in contrast to trypsin, which has Gly residues
at these positions. The conformation of Asn682(216) is
stabilized by interaction with Glu648(184) buried inside
the pocket. 2) Residue 655 in the base of the pocket in MSP is Gly,
whereas in trypsin it is Asp, which interacts with the scissile bond
Lys of the substrate. Thus, the model suggests that the receptor
binding region of MSP does not include the base of the S1 pocket but
involves the entrance.
Characterization of MSP Produced by CHO Cells Stably Transfected
with Wild Type and Mutated MSP cDNAs--
Two MSP mutants were
generated, a double mutant of residues that stabilize the shape of the
S1 pocket (E648G/N682G) and a mutation of Arg683 (R683Q),
adjacent to the entrance to the S1 pocket. Wild type and mutated MSP
cDNAs were cloned into the eukaryotic expression vector pCl-neo,
and stable CHO cell transfectants were generated. Serum-containing
medium from the transfected cells was used as a source of wild type and
mutant MSP. We selected clones that produced equal amounts of wild type
or mutant MSP, and by sandwich ELISA the concentration in the medium
was 0.5 nM (data not shown). The products were further
characterized by SDS-PAGE. Culture fluids from
35S-metabolically labeled CHO cell transfectants were
immunoprecipitated by rabbit anti-MSP antibodies and analyzed by
SDS-PAGE under non-reducing and reducing conditions (Fig.
3). In confirmation of the sandwich ELISA
results, the intensity of the bands in Fig. 3 shows that the selected
CHO cell clones produce comparable amounts of wild type or mutated MSP.
SDS-PAGE under reducing conditions shows that there is no 80-kDa
pro-MSP in CHO supernatants. Only two bands at molecular mass positions
of approximately 60 and 30 kDa corresponding to MSP
and
chains
were visualized (Fig. 3B). This is due to the fact that
recombinant pro-MSP is cleaved to MSP in supernatants of CHO cells
cultured in medium containing serum (17). The absence of an 80-kDa band
under non-reducing conditions (Fig. 3A) demonstrates that
the
and
chains of these recombinant products are not
disulfide-linked, in contrast to 
chain heterodimeric native MSP.
This is due to the fact that in recombinant pro-MSP,
chain
Cys588 may form an intrachain disulfide with
Cys672 instead of with
chain Cys468 (19,
33).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis by SDS-PAGE under non-reduced
(A) and reduced (B) conditions of
35S-labeled MSP produced by CHO cells. CHO cells with
stably expressed wild type (WT) or mutated MSP were
metabolically labeled with [35S]methionine and -cysteine.
35S-Labeled MSP was immunoprecipitated from 1 ml of CHO
tissue culture supernatants by rabbit anti-MSP antibodies coupled to
Sepharose beads. Immunoprecipitated proteins were separated by 4-12%
gradient SDS-PAGE under non-reducing (A) and reducing
(B) conditions and detected by radioautography.
Arrows indicate the position of MSP and chains.
Their presence under non-reducing conditions shows that they are not
disulfide-linked. The band at about 90 kDa is not an MSP protein.
|
|
Binding of Wild Type and Mutated MSP
Chain to RON--
To
determine the capacity of wild type and mutated MSP
chain to
interact with receptor, MDCK-RE7 cells with overexpressed RON and
parental MDCK cells as a control were equilibrated with 35S-labeled CHO cell supernatants containing 0.5 nM free
and
chain. After equilibration, cells were
washed and lysed. Cell-bound MSP chains were immunoprecipitated by
rabbit anti-MSP antibodies which recognize both
and
chains
(28). Precipitated MSP chains were analyzed by SDS-PAGE, and protein
bands were visualized by radioautography. Results for RE7 lysates (Fig.
4A) showed an intense wild
type MSP
chain band, a faint band for
chain mutated in the S1
pocket, and no band for the R683Q mutant. Densitometry of the
chain
bands showed that the amount of double mutant E648G/N682G bound was
about 50 times less than bound wild type
chain; no R683Q band was
detected. There was no MSP
chain binding to parental MDCK cells,
which do not express detectable RON (9). Interaction of
35S-labeled
chain from CHO supernatants was inhibited
by either unlabeled MSP or free
chain (Fig. 4B). This
result suggested that we were observing saturable binding of
chain
to RON, a conclusion supported by the absence of binding to MDCK cells. The diminished or absent
chain mutant bands in Fig. 4A
therefore reflect diminished or undetectable binding of the mutants to
RON.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 4.
A, binding of 35S-labeled
wild type (WT) and mutated MSP to RON. MDCK-RE7 cells
(5 × 106) with stably expressed RON receptor or
parental MDCK cells without detectable RON were equilibrated for 4 h at 4 °C in 5 ml of CHO tissue culture supernatants containing
35S-labeled wild type or mutated MSP. Cell-bound
35S-MSP was immunoprecipitated with rabbit anti-MSP
antibodies coupled to Sepharose beads. Immunoprecipitated proteins were
separated by 4-12% gradient SDS-PAGE, and protein bands were
visualized by radioautography. B, MSP and free chain
compete with 35S-labeled wild type or mutated MSP for
binding to RON. MDCK-RE7 cells were equilibrated for 4 h at
4 °C in 5 ml of CHO supernatants containing 35S-labeled
wild type or mutated MSP in the presence of excess unlabeled MSP, chain or chain. Cell-bound labeled MSP was detected as described
for A.
|
|
Binding of Free
Chain to MDCK-RE7 Cells--
In addition to
the
chain, we detected binding of free
chain to RON-expressing
cells (Fig. 4A, upper band). Reasons to suggest that the
observed band represents MSP
chain are as follows: 1) an
appropriate molecular mass; 2) no band in the case of supernatants from
metabolically labeled CHO cells transfected with vector alone, which
therefore do not express MSP; and 3) no band with supernatants of
MSP-transfected cells that were equilibrated with parental MDCK cells,
which do not express RON. Comparison of the band intensities in Fig.
4A shows that the amount of bound
chain is only a small fraction of the amount of bound
chain. Therefore it was important to determine whether the band reflected binding of free
chain or a
small amount of MSP 
chain heterodimer binding via the
chain.
Two facts weighed against the latter possibility. First, as noted
above, SDS-PAGE of metabolically labeled transfected CHO cell
supernatants did not reveal any trace of 
chain MSP. Second,
despite no sign of MSP mutant R683Q
chain binding, the
chain
band was detectable (Fig. 4A). To obtain independent
evidence that free
chain can interact with RON, a binding assay of
purified recombinant
chain was performed. MDCK-RE7 cells or MDCK
cells as a control were equilibrated for 4 h at 4 °C with 5 nM free recombinant
chain or disulfide-linked 
chain MSP. Then bound 
chain MSP or
chain was
immunoprecipitated with mouse monoclonal 2 S anti-MSP, which
recognizes only
chain (28). Immunoprecipitated
chain was
detected on a blot with rabbit anti-MSP antibodies after SDS-PAGE and
transfer of proteins to a nitrocellulose membrane. Fig.
5A shows binding of free
chain to RE-7 cells, which is a small fraction of the amount of
chain detected after 
chain MSP was equilibrated with the cells.
In both cases, binding is RON-dependent, as shown by the
absence of bands from MDCK cell lysates. It was also important to
consider the possibility that the bound
chain line came from
binding of a small amount of 
MSP that contaminates the
chain
preparation. This was ruled out by SDS-PAGE of the same cell
immunoprecipitates under non-reducing conditions. If the
chain
detected in Fig. 5A (under reducing conditions) were due
entirely to bound 
chain contaminating the
chain preparation,
non-reducing SDS-PAGE should show an 
line and no
. The
converse is the case (Fig. 5B). For the
chain lane, at
an ECL exposure that shows an
chain line comparable in intensity to
that of Fig. 5A, there is no detectable 
line. At
longer exposure times we see an 
line and a much more intense
chain line. The latter reflects binding of free
chain to the RE-7
cells; the former is due to the small amount of 
chain contaminating the
chain preparation and is a small fraction of the
total bound
chain.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
Interaction of MSP free chain with RON. MDCK-RE7 cells or MDCK cells as a control
were equilibrated for 4 h at 4 °C in 5 nM
recombinant MSP or free chain. Cell-bound MSP or chain was
immunoprecipitated (IP) by mouse monoclonal anti-MSP
antibody (that reacts with an chain epitope) coupled to Sepharose.
Immunoprecipitated proteins were separated by 7.5% SDS-PAGE under
reducing (A) and non-reducing (B) conditions.
Protein bands were detected by Western blotting (WB) with
rabbit anti-MSP antibodies. For the MSP standard, 5 nM MSP
was directly immunoprecipitated with mouse monoclonal anti-MSP. The
left and right blots in B illustrate
results of short and long exposures.
|
|
Quantitative Analysis of MSP,
and
Chain Binding to the RON
Receptor--
In addition to the above experiments on binding of MSP
and its chains to cells expressing RON, we quantified by sandwich ELISA the binding of disulfide-linked 
chain MSP and free
and
chains to recombinant mouse RON receptor adsorbed to wells of a
microtiter plate. Binding of each ligand was tested in duplicate in
three separate experiments, and concentration-dependent
binding curves were generated (Fig. 6).
Mean EC50 values calculated from curves of the three
experiments (31) are shown in the inset of Fig. 6.
Disulfide-linked 
chain MSP has a somewhat higher affinity for
RON than free
chain, a result comparable to binding data for
RON-expressing cells (24). In contrast, free
chain binds to RON
with a much lower affinity, as reflected in an EC50 that is
2 orders of magnitude higher than the value for MSP. Thus, MSP has two
separate binding sites with high and low affinity, located in
and
chains, respectively.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Concentration-dependent binding
of recombinant disulfide-linked  chain MSP and free and chains to the RON receptor adsorbed to wells of a
microtiter plate and measured in an ELISA as described under
"Experimental Procedures." Each value represents the mean ± S.E. of three independent experiments.
|
|
 |
DISCUSSION |
The MSP
chain three-dimensional model enabled us to consider
possible loci for RON high affinity binding by analogy to
substrate-enzyme interactions in the family of chymotrypsin-like serine
proteases. In zymogens of the family the catalytic triad is formed, but
the substrate-binding site is not fully shaped. MSP is able to bind RON
with high affinity only after proteolytic cleavage, which in zymogens
causes conformational changes leading to formation of a mature binding
site (Fig. 2). Thus residues critical for receptor binding should
correspond to those that define the subsite preference at the scissile
bond of substrate. According to the model, the S1 pocket in MSP is
filled by interacting pair Glu648 and Asn682,
leaving only a shallow cavity for interaction with the substrate side
chain. In addition to a double mutant of the Glu/Asn pair (E648G/N682G), we made a single mutant of Arg683 located at
the entrance to the S1 pocket. We mutated Arg683 to Gln,
which is also hydrophilic and has side chain length comparable to that
of Arg. Thus mutation of Arg683 to Gln was not expected to
affect the structure of the
chain. The fact that mutation of
Arg683 alone completely abolished
chain binding to RON
(Fig. 4A) suggests that this residue is directly involved in
receptor binding. Such a profound effect caused by a single site
mutation is not surprising in view of the fact that mutation of a
single residue of human growth hormone receptor (34) or HGF
chain
(see below) caused loss of binding to their respective ligands. Binding
of
chain mutant E648G/N682G is about 50 times less than the binding
of
chain wild type. The diminished binding of the double mutant (E648G/N682G) suggests that these residues are required to stabilize the
chain structure in this region. Our results show that the region corresponding to an enzyme S1 site is essential for
chain binding to RON. Other features affecting specificity of MSP-receptor interactions may involve residues from loops 1-3 (shown in Fig. 2A), which influence substrate specificity and catalytic
efficiency of the trypsin-like serine proteases (26). It is noteworthy that six Arg side chains from loops 2 and 3 form a prominent cluster of
positive charge on the MSP
chain surface in the neighborhood of the
S1 site.
We recently proposed that both HGF and MSP have two receptor binding
sites of different affinity, one on the
chain and one on the
chain, and that Met and RON dimerization can be induced by a single
ligand molecule (27). The site on the
chain becomes available for
binding only after proteolytic cleavage of the single chain precursors.
For HGF, the high affinity site is on the
chain and the postulated
low affinity site is on the
chain. The converse is the case for
MSP. Comparison of our model of the MSP
chain structure with that
of the HGF
chain shows that, in contrast to MSP, the opening of the
HGF S1 pocket is not blocked; and there are differences in the surface
loops, as described in the legend of Fig. 2A. These
differences in the S1 pocket and neighboring surface loops could
account for the inability of HGF to bind via its
chain to RON
(35).
This communication provides the first evidence that free MSP
chain
interacts with the RON receptor (Figs. 4A, 5, and 6). We
previously reported undetectable binding to RON-expressing cells by a
125I-labeled aliquot of the same
chain preparation used
in the current study (24). We attribute this to a lower sensitivity of
the former method. After cells were equilibrated with equimolar concentrations of free
and
chains, bound
chain was less than 10% of bound
chain (determined by densitometry of the blot shown in Fig. 4A). The published binding curves of iodinated
MSP or
chain show that 10% of the observed values would be
indistinguishable from background (24). We quantified binding of MSP
and its free
and
chains to recombinant RON adsorbed to
microtiter wells. Results show that MSP has two binding sites with low
(EC50 = 16.9 nM) and high (EC50 = 0.25 nM) affinity, located in
and
chains respectively.
Despite binding of free
chain or
chain to RON, neither chain
can replicate the action of the disulfide-linked heterodimer. Wang
et al. (24) reported that whereas mature MSP caused tyrosine phosphorylation of RON and a cellular biological response, these effects were not induced by strongly binding free
chain or by
chain. In our case, the low level of
chain binding to
RON-expressing cells also did not induce RON tyrosine phosphorylation
(data not shown). How does 
chain MSP cause RON dimerization? The
fact that the
chain and
chain are each capable of interacting
with RON suggests that MSP is bivalent, with a high affinity locus on
the
chain and a low affinity site on the
chain. The
contribution of the
chain to the binding strength of MSP to RON was
suggested by an MSP binding Kd that was
significantly lower than the Kd for free
chain
(24). As noted above, we proposed that a RON dimer could be formed by a
single MSP molecule that could bind to RON via the
chain, after
which a second RON could interact with the
chain. The converse
sequence was suggested for HGF. This is the model that has been
confirmed for induction of receptor dimerization by growth hormone
(36). The finding that the
chain can bind to RON supports our
proposed model.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Tom L. Blundell and colleagues
for providing us with the coordinates of the HGF
chain
three-dimensional model. We also thank Dr. Teizo Yoshimura for the MSP
cDNA and Alison Skeel for technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by funds from the National
Cancer Institute, DHHS, under contract with ABL (to M. M.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: NCI-FCRDC, Bldg.
560/Rm. 12-46, Frederick, MD 21702. Tel.: 301-846-1560; Fax: 301-846-6145; E-mail:danilkovitch@mail.ncifcrf.gov.
2
A. Skeel and E. J. Leonard, unpublished data.
3
MSP residue numbers in the text are followed in
parentheses by the corresponding bovine trypsin residue number.
 |
ABBREVIATIONS |
The abbreviations used are:
MSP, macrophage-stimulating protein;
HGF/SF, hepatocyte growth
factor/scatter factor;
MDCK, Madin-Darby canine kidney;
CHO, Chinese
hamster ovary;
ELISA, enzyme-linked immunosorbent assay;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Skeel, A.,
Yoshimura, T.,
Showalter, S.,
Tanaka, S.,
Appella, E.,
and Leonard, E.
(1991)
J. Exp. Med.
173,
1227-1234[Abstract/Free Full Text]
|
| 2.
|
Yoshimura, T.,
Yuhki, N.,
Wang, M.-H.,
Skeel, A.,
and Leonard, E. J.
(1993)
J. Biol. Chem.
268,
15461-15468[Abstract/Free Full Text]
|
| 3.
|
Han, S.,
Stuart, L. A.,
and Degen, S. J. F.
(1991)
Biochemistry
30,
9768-9780[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Leonard, E. J.
(1997)
in
Plasminogen-related Growth Factors
(Bock, G. R.
, and Goode, J. A., eds)
, pp. 183-191, John Wiley & Sons, Inc., New York
|
| 5.
|
Leonard, E. J.,
and Skeel, A.
(1976)
Exp. Cell Res.
102,
434-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Wang, M.-H.,
Cox, G. W.,
Yoshimura, T.,
Sheffler, L. A.,
Skeel, A.,
and Leonard, E. J.
(1994)
J. Biol. Chem.
269,
14027-14031[Abstract/Free Full Text]
|
| 7.
|
Danilkovitch, A.,
and Leonard, E. J.
(1999)
J. Leukocyte Biol.
65,
345-348[Abstract]
|
| 8.
|
Ronsin, C.,
Muscatelli, F.,
Mattei, M. G.,
and Breathnach, R.
(1993)
Oncogene
8,
1195-1202[Medline]
[Order article via Infotrieve]
|
| 9.
|
Wang, M.-H.,
Ronsin, C.,
Gesnel, M.-C.,
Coupey, L.,
Skeel, A.,
Leonard, E. J.,
and Breathnach, R.
(1994)
Science
266,
117-119[Abstract/Free Full Text]
|
| 10.
|
Wang, M.-H.,
Iwama, A.,
Skeel, A.,
Suda, T.,
and Leonard, E. J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
3933-3937[Abstract/Free Full Text]
|
| 11.
|
Iwama, A.,
Wang, M.-H.,
Yamaguchi, N.,
Okano, K.,
Sudo, T.,
Gervais, F.,
Morissette, C.,
Leonard, E. J.,
and Suda, T.
(1995)
Blood
86,
3394-3403[Abstract/Free Full Text]
|
| 12.
|
Matsumoto, K.,
and Nakamura, T.
(1992)
Crit. Rev. Oncog.
3,
27-54[Medline]
[Order article via Infotrieve]
|
| 13.
|
Park, M.,
Dean, M.,
Kaul, K.,
Braun, M. J.,
Gonda, M. A.,
and Vande Woude, G.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
6379-6383[Abstract/Free Full Text]
|
| 14.
|
Matsumoto, K.,
and Nakamura, T.
(1997)
Biochem. Biophys. Res. Commun.
239,
639-644[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Jeffers, M.,
Rong, S.,
and Woude, G. F.
(1996)
J. Mol. Med.
74,
505-513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Schmidt, L.,
Duh, F. M.,
Chen, F.,
Kishida, T.,
Glenn, G.,
Choyke, P.,
Scherer, S. W.,
Zhuang, Z.,
Lubensky, I.,
Dean, M.,
Allikmets, R.,
Chidambaram, A.,
Bergerheim, U. R.,
Feltis, J. T.,
Casadevall, C.,
Zamarron, A.,
Bernues, M.,
Richard, S.,
Lips, C. J.,
Walther, M. M.,
Tsui, L. C.,
Geil, L.,
Orcutt, M. L.,
Stackhouse, T.,
and Zbar, B.
(1997)
Nat. Genet.
16,
68-73[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Wang, M.-H.,
Yoshimura, T.,
Skeel, A.,
and Leonard, E. J.
(1994)
J. Biol. Chem.
269,
3436-3440[Abstract/Free Full Text]
|
| 18.
|
Bezerra, J. A.,
Witte, D. P.,
Aronow, B. J.,
and Degen, S. J.
(1993)
Hepatology
18,
394-399[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Yoshikawa, W.,
Hara, H.,
Takehara, T.,
Shimonishi, M.,
Sakai, H.,
Shimizu, N.,
Shimizu, S.,
Wang, M.-H.,
Hagiya, M.,
Skeel, A.,
and Leonard, E. J.
(1999)
Arch. Biochem. Biophys.
363,
356-360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Nanney, L. B.,
Skeel, A.,
Luan, J.,
Polis, S.,
Richmond, A.,
Wang, M.-H.,
and Leonard, E. J.
(1998)
J. Invest. Dermatol.
111,
573-581[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Donate, L. E.,
Gherardi, E.,
Srinivasan, N.,
Sowdhamini, R.,
Aparicio, S.,
and Blundell, T. L.
(1994)
Protein Sci.
3,
2378-2394[Abstract]
|
| 22.
|
Sakata, H.,
Stahl, S. J.,
Taylor, W. G.,
Rosenberg, J. M.,
Sakaguchi, K.,
Wingfield, P. T.,
and Rubin, J. S.
(1997)
J. Biol. Chem.
272,
9457-9463[Abstract/Free Full Text]
|
| 23.
|
Lokker, N. A.,
Presta, L. G.,
and Godowski, P. J.
(1994)
Protein Eng.
7,
895-903[Abstract/Free Full Text]
|
| 24.
|
Wang, M. H.,
Julian, F. M.,
Breathnach, R.,
Godowski, P. J.,
Takehara, T.,
Yoshikawa, W.,
Hagiya, M.,
and Leonard, E. J.
(1997)
J. Biol. Chem.
272,
16999-17004[Abstract/Free Full Text]
|
| 25.
|
Waltz, S. E.,
McDowell, S. A.,
Muraoka, R. S.,
Air, E. L.,
Flick, L. M.,
Chen, Y. Q.,
Wang, M. H.,
and Degen, S. J.
(1997)
J. Biol. Chem.
272,
30526-30537[Abstract/Free Full Text]
|
| 26.
|
Perona, J. J.,
and Craik, C. S.
(1997)
J. Biol. Chem.
272,
29987-29990[Free Full Text]
|
| 27.
|
Miller, M.,
and Leonard, E. J.
(1998)
FEBS Lett.
429,
1-3[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Wang, M.-H.,
Skeel, A.,
Yoshimura, T.,
Copeland, T. D.,
Sakaguchi, K.,
and Leonard, E. J.
(1993)
J. Leukocyte Biol.
54,
289-295[Abstract]
|
| 29.
|
Jones, A.
(1985)
Methods Enzymol.
115,
157-171[Medline]
[Order article via Infotrieve]
|
| 30.
|
Brunger, A.
(1992)
X-PLOR: A System for X-ray Crystallography and NMR, version 3.1
, Yale University Press, New Haven, CT
|
| 31.
|
Jin, L.,
Fendly, B. M.,
and Wells, J. A.
(1992)
J Mol. Biol.
226,
851-865[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Khan, A. R.,
and James, M. N.
(1998)
Protein Sci.
7,
815-836[Abstract]
|
| 33.
|
Wahl, R. C.,
Costigan, V. J.,
Batac, J. P.,
Chen, K.,
Cam, L.,
Courchesne, P. L.,
Patterson, S. D.,
Zhang, K.,
and Pacifici, R. E.
(1997)
J. Biol. Chem.
272,
15053-15056[Abstract/Free Full Text]
|
| 34.
|
Clackson, T.,
and Wells, J. A.
(1995)
Science
267,
383-386[Abstract/Free Full Text]
|
| 35.
|
Wang, M.-H.,
Iwama, A.,
Dlugosz, A. A.,
Sun, Y.,
Skeel, A.,
Yuspa, S. H.,
Suda, T.,
and Leonard, E. J.
(1996)
Exp. Cell Res.
226,
39-46[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
de Vos, A. M.,
Ultsch, M.,
and Kossiakoff, A. A.
(1992)
Science
255,
306-312[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.